These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 30246766)

  • 1. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
    Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
    Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Elmasry S; Wadhwa S; Bang BR; Cook L; Chopra S; Kanel G; Kim B; Harper T; Feng Z; Jerome KR; Kahn JA; Saito T
    Gastroenterology; 2017 Feb; 152(3):550-553.e8. PubMed ID: 27838287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
    Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?
    Naguib H; Abouelnaga SF; Elsayed MM
    Int Urol Nephrol; 2024 Jan; 56(1):217-222. PubMed ID: 37209238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.
    Ibrahim Mohammed Ebid AH; Ashraf Ahmed O; Hassan Agwa S; Mohamed Abdel-Motaleb S; Mohamed Elsawy A; Hagag RS
    J Clin Pharm Ther; 2020 Jun; 45(3):539-546. PubMed ID: 31889322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.
    Ahmed OA; Elsebaey MA; Fouad MHA; Elkadeem M; Badawi R; Khayyal A; Soliman S; Negm MS; Abd-Elsalam S
    Infect Disord Drug Targets; 2020; 20(3):389-395. PubMed ID: 30569878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
    Abdallah F; Mohamed G; Ibrahim M; El Tarabily M
    Am J Med Sci; 2018 May; 355(5):456-466. PubMed ID: 29753376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
    Sarrazin C; Isakov V; Svarovskaia ES; Hedskog C; Martin R; Chodavarapu K; Brainard DM; Miller MD; Mo H; Molina JM; Sulkowski MS
    Clin Infect Dis; 2017 Jan; 64(1):44-52. PubMed ID: 27737953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.
    Hong CM; Liu CH; Su TH; Yang HC; Chen PJ; Chen YW; Kao JH; Liu CJ
    J Microbiol Immunol Infect; 2020 Aug; 53(4):569-577. PubMed ID: 30316726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.
    Eletreby R; Elakel W; Said M; El Kassas M; Seif S; Elbaz T; El Raziky M; Abdel Rehim S; Zaky S; Fouad R; Gamal Eldeen H; Abdo M; Korany M; Yosry A; El Serafy M; El-Sayed MH; ElShazly Y; Waked I; Doss W; Esmat G
    Liver Int; 2017 Apr; 37(4):534-541. PubMed ID: 27712017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.